FINWIRES · TerminalLIVE
FINWIRES

Oncolytics Biotech Aligns With FDA on Study Design for Pelareorep in Anal Cancer

By

-- Oncolytics Biotech (ONCY) said Monday a meeting with the US Food and Drug Administration has led to agreement on how to design a trial to support approval of pelareorep for patients with unresectable metastatic squamous cell carcinoma of the anal canal.

The company added that it will use the regulator's feedback to finalize the study plan. The trial is expected to be a single randomized controlled study that could support both accelerated approval and full approval at different stages, the company said.

Price: $1.07, Change: $+0.04, Percent Change: +3.88%

Related Articles

Australia

Capitol Federal Financial Maintains Quarterly Dividend

Capitol Federal Financial (CFFN) said Tuesday it maintained its quarterly dividend at $0.085 per share, payable May 15 to stockholders of record May 1.The company repurchased nearly 3.1 million common shares at an average cost of $7.27 apiece from Jan. 1 to April 22, 2026, according to a statement.The company said it will release financial results for the quarter ended March 31 on April 29.Price: $7.86, Change: $-0.02, Percent Change: -0.32%

$CFFN
Insider Trading

Union Pacific Insider Sold Shares Worth $7,442,691, According to a Recent SEC Filing

Kenyatta G Rocker, Executive Vice President, Marketing and Sales, on April 24, 2026, sold 27,387 shares in Union Pacific (UNP) for $7,442,691. Following the Form 4 filing with the SEC, Rocker has control over a total of 64,792 common shares of the company, with 61,102 shares held directly and 3,690 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/100885/000010088526000158/xslF345X05/edgardoc.xmlPrice: $268.39, Change: $-0.52, Percent Change: -0.19%

$UNP
Insider Trading

Union Pacific Insider Sold Shares Worth $549,400, According to a Recent SEC Filing

Jennifer L Hamann, Chief Financial Officer & Executive Vice President, on April 24, 2026, sold 2,000 shares in Union Pacific (UNP) for $549,400. Following the Form 4 filing with the SEC, Hamann has control over a total of 120,329 common shares of the company, with 114,642 shares held directly and 5,687 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/100885/000010088526000159/xslF345X05/edgardoc.xmlPrice: $268.52, Change: $-0.39, Percent Change: -0.15%

$UNP